Fampridine as an immunomodulator

You asked is fampridine a DMT and MD2 thought why would a symptom control drug work as a DMT.

Some potassim channels are on immune cells and so blocking them may be of value and there is a literature on potassium channels

Treatment of multiple sclerosis with a combination of laquinimod and fampridine patent WO2013US50001 20130711.

4-amino pyridine is the active part of fampridine which is a slow release formualtion of 4-AP.
Are the  lines with the crosses (4-AP) really different from the small circle? So if we listen to the ARRIVE guidelines for EAE you should ask...Where is the evidence of variation i.e. the standard deviations because without them you cannot tell how good the data is and without knowing how many animals got sick and to what severity they got the lines are relativiely meaning less.

Baker D, Amor S. Publication guidelines for refereeing and reporting on animal use in experimental autoimmune encephalomyelitis.J Neuroimmunol. 2012 Jan 18;242(1-2):78-83.

The "smack you in the eye test" looks like the peak of vehicle verses 4-AP (2.5mg/kg is no difference) probably true at 5mg/kg and is the really any difference between Laquinimod alone and laquinimod + fampridine. The sack you in the eye test say no to me what does it say to you? However the patent is all about the added value of mixing the two compounds.  This is patent is not peer reviewed properly and one should asked about the value of mixing a DMT with low efficacy with a symptom control drug in an assay aided at showing a DMT-like effect.

Is there a "building-site" effect.......The animals feel like crap and so are stressed-out (as occurs due to construction work  nearby) and so the steroid response inhibits EAE or is it a real immunomodulator effect.

Others think not and say 4-AP has no effect on EAE
Göbel K, Wedell JH, Herrmann AM, Wachsmuth L, Pankratz S, Bittner S, Budde T, Kleinschnitz C, Faber C, Wiendl H, Meuth SG. 4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis. Exp Neurol. 2013; 248:62-71.

Uitdehaag BM, Polman CH, de Groot CJ, Dijkstra CD. Effect of K+ channel blockers on the clinical course and histological features of experimental allergic encephalomyelitis.Acta Neurol Scand. 1994; 90:299-301.

others say

Judge SI, Yeh JZ, Mannie MD, Pope Seifert L, Paterson PY.
Potassium Channel Blockers Inhibit Adoptive Transfer of Experimental Allergic Encephalomyelitis by Myelin-Basic-Protein-Stimulated Rat T Lymphocytes. J Biomed Sci. 1997; 4:169-178.

The effect of fapridine on the course of MS is something that we would like to know.

Labels: